This is a randomized Phase I/II study of indinavir (protease inhibitor) and DMP266 (non-nucleoside RT inhibitor) in patients with CD4 cells between 100-500 and viral load> 20,000 copies/ML. Treatments will be evaluated by viral load, CD4 cell changes and pharmacokinetics. The objective of the study is to evaluate the safety, tolerability, anti-viral activity of DMP266 alone and in combination with indinavir and to characterize the development of resistance to DMP266 by genotypic change of resistant status.
Showing the most recent 10 out of 553 publications